BioGaia: One of the World’s Most Widespread Infections – BioGaia’s Gastrus Improves Treatment

16-12-2013 Business Wire HealthComments (0)

Biotechnology

Regulatory News: BioGaia (STO:BIOG-B): Two new studies in patients infected with Helicobacter pylori show that supplementation with the new probiotic Lactobacillus reuteri Gastrus reduced side effects of eradication therapy by a third. "We found that Gastrus is able to exert an inhibitory effect on H. pylori growth and that when administered with the eradication therapy, it induces a significant reduction of antibiotic associated side effects and increases eradicat

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top